Pub. Date : 2012 Nov
PMID : 22819196
11 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | UNLABELLED: (111)In-DTPA-anti-gammaH2AX-Tat, which combines an anti-gammaH2AX antibody with a cell-penetrating peptide, Tat, and the Auger electron-emitting radioisotope, (111)In, targets the DNA damage signalling protein, gammaH2AX, and has potential as a probe for imaging DNA damage in vivo. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 2 | UNLABELLED: (111)In-DTPA-anti-gammaH2AX-Tat, which combines an anti-gammaH2AX antibody with a cell-penetrating peptide, Tat, and the Auger electron-emitting radioisotope, (111)In, targets the DNA damage signalling protein, gammaH2AX, and has potential as a probe for imaging DNA damage in vivo. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 3 | UNLABELLED: (111)In-DTPA-anti-gammaH2AX-Tat, which combines an anti-gammaH2AX antibody with a cell-penetrating peptide, Tat, and the Auger electron-emitting radioisotope, (111)In, targets the DNA damage signalling protein, gammaH2AX, and has potential as a probe for imaging DNA damage in vivo. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 4 | The goal of this study was to investigate whether (111)In-DTPA-anti-gammaH2AX-Tat labelled to high specific activity (6MBq/mug) can amplify treatment-related DNA damage for therapeutic gain. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 5 | METHODS: MDA-MB-468 and MDA-MB-231/H2N (231-H2N) breast cancer cells were incubated with (111)In-DTPA-anti-gammaH2AX-Tat (3MBq, 6MBq/mug) or a control radioimmunoconjugate, (111)In-DTPA-mIgG-Tat, and exposed to IR or bleomycin. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 6 | (111)In-DTPA-anti-gammaH2AX-Tat was administered intravenously to 231-H2N-xenograft-bearing Balb/c nu/nu mice in tumor growth inhibition studies. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 7 | Similarly, bleomycin (25-200mug/mL) plus (111)In-DTPA-anti-gammaH2AX-Tat resulted in a lower SF compared to bleomycin alone. | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 8 | The combination of a single exposure to IR (10Gy) plus (111)In-DTPA-anti-gammaH2AX-Tat significantly decreased the growth rate of 231-H2N xenografts in vivo compared to either (111)In-DTPA-anti-gammaH2AX-Tat or IR alone (-0.002+-0.004 versus 0.036+-0.011 and 0.031+-0.014mm(3)/day, respectively, P<.001). | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 9 | The combination of a single exposure to IR (10Gy) plus (111)In-DTPA-anti-gammaH2AX-Tat significantly decreased the growth rate of 231-H2N xenografts in vivo compared to either (111)In-DTPA-anti-gammaH2AX-Tat or IR alone (-0.002+-0.004 versus 0.036+-0.011 and 0.031+-0.014mm(3)/day, respectively, P<.001). | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 10 | The combination of a single exposure to IR (10Gy) plus (111)In-DTPA-anti-gammaH2AX-Tat significantly decreased the growth rate of 231-H2N xenografts in vivo compared to either (111)In-DTPA-anti-gammaH2AX-Tat or IR alone (-0.002+-0.004 versus 0.036+-0.011 and 0.031+-0.014mm(3)/day, respectively, P<.001). | Pentetic Acid | H2A.X variant histone | Mus musculus |
| 11 | CONCLUSION: (111)In-DTPA-anti-gammaH2AX-Tat amplifies anticancer treatment-related DNA damage in vitro and has a potent anti-tumor effect when combined with IR in vivo. | Pentetic Acid | H2A.X variant histone | Mus musculus |